GlaxoSmithKline says it has shut down one of its two manufacturing facilities in India after offering all workers there early …
GlaxoSmithKline’s severe asthma drug mepolizumab has impressed in a mid-stage study, meaning it can now progress into Phase III testing. …

GlaxoSmithKline has divested the majority of its Australian generics unit to Aspen Global, a firm it partly owns. The South …

Pfizer has been fined $60 million for making improper payments to doctors in Europe, Asia and the Middle East. The …
GlaxoSmithKline has gained a new European licence for its cancer pill Votrient adding to its renal cell carcinoma licence. The …

GlaxoSmithKline has submitted its two investigational melanoma drugs to regulators in both Europe and the US. The firm is seeking …
London 2012 could provide a boost in the continuing search for personalised medicines for diabetes, heart disease and dementia as …
GlaxoSmithKline posted a loss in its second quarter results, as pressure in mature markets continues to affect the firm. Pharmaceutical …

GlaxoSmithKline is to increase ownership in Amicus Therapeutics as the firms extend their collaboration to find a new drug for …

GlaxoSmithKline has finally sealed the acquisition of Human Genome Sciences, the company with which it co-markets lupus treatment Benlysta. The …
GlaxoSmithKline and US biopharma firm Theravance have submitted their investigational chronic obstructive pulmonary disease (COPD) drug to regulators in Europe …

GlaxoSmithKline has launched a UK advertising campaign to celebrate the role anti-doping science will play in keeping the Games as …

Court papers surrounding GSK’s $3 billion fraud charge make for grim reading, and further damages an industry that already struggles …
GlaxoSmithKline will pay $3 billion in fraud charges, the largest of its kind in US history. The charges relate to …

GSK and partner Theravance have released new data for its combination COPD drug. Results from four late-stage trials suggest that …